GCAN
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company was founded in 2014 and is based in Baltimore, Maryland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.00 | $0 | -$4,376 |
| 2025 Q4 | 0.04 | $0 | -$24,140 |
| 2025 Q3 | -0.04 | $0 | -$5,357 |
| 2025 Q2 | -0.00 | $0 | -$19,501 |
| 2025 Q1 | -0.00 | $0 | -$11,155 |
| 2024 Q4 | -0.00 | $5,000 | -$4,914 |
| 2024 Q3 | -0.00 | $0 | -$18,034 |
| 2024 Q2 | -0.00 | $0 | -$37,536 |